About
Name | Glen Baker |
University | |
Website | psychiatry.med.ualberta.ca/AboutUs/DepartmentMembers/Academic/Baker.aspx |
Research Keywords | biomarkers in psychiatric and neurological disorders, neurochemistry of depression, schizophrenia and anxiety disorders, drug metabolism and drug interactions, neuroprotective drugs |
Additional Information
Lab Methodologies |
|
Apparatus |
|
Roles and Connections
Primary Role | |
CAN Connections |
Most Cited Publications
Matveychuk D, MacKenzie EM, Kumpula D, Song MS, Holt A, Kar S, Todd KG, Wood PL, Baker GB, "Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine." Cellular and molecular neurobiology 42,1 (2022 Jan): 225-242 |
MacKay MB, Paylor JW, Wong JTF, Winship IR, Baker GB, Dursun SM, "Multidimensional Connectomics and Treatment-Resistant Schizophrenia: Linking Phenotypic Circuits to Targeted Therapeutics." Frontiers in psychiatry 9, (2018): 537 |
Matveychuk D, Thomas RK, Swainson J, Khullar A, MacKay MA, Baker GB, Dursun SM, "Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers." Therapeutic advances in psychopharmacology 10, (2020): 2045125320916657 |